tirzepatide compounding update Compounders lose battle over Eli Lilly weight loss drug and FDA shortage list Compounded Tirzepatide vs Mounjaro/Zepbound: 75%

Although a PBM may list the drug on their formulary, the decision to provide coverage for the medication still falls upon the plan sponsor. In addition, payers should: Review PBM formulary and utilization management systems to ensure that only clinically eligible patients get the drugs Negotiate lowest-net-cost PBM formulary changes to obtain the medications at the lowest prices Contract with a PBM that approves of manufacturer copay cards for non-specialty drugs, which can lower the cost burden on the payer The weight loss potential cannot be easily dismissed on either a clinical or financial basis, according to the guide

Others include Zepbound on their formulary but require prior authorization and proof of medical necessity before they approve it

S3a, b)

Here, an intestinal enzyme known as -glutamyltransferase rapidly hydrolyzes (breaks down) the tripeptide structure of glutathione into its constituent amino acids before it can be absorbed intact